HPV Vaccination Best Practices Learning Collaborative
Download the HPV Vaccination Best Practices Learning Collaborative Summary Report and Lessons Learned White Paper hereDownload White Paper
AMGA and the National HPV Vaccination Roundtable launched an 18-month learning collaborative to improve HPV vaccination rates among adolescents served by medical groups and integrated health systems. This Collaborative is based off the successful work undertaken in AMGA’s Adult Immunization Best Practices Learning Collaborative which resulted in 5.5 million vaccinations administered or documented over a three year period. Funding for the learning collaborative was made possible by the Office of Infectious Disease and HIV/AIDS Policy (OIDP) via the Centers for Disease Control and Prevention under CFDA # 93.421 - Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health, Cooperative Agreement grant number 6 NU38OT000283-02-01.
Eight healthcare organizations were recruited to participate in the collaborative and to implement best practice interventions and strategies.
What We Already Know
Fourteen-million Americans acquire HPV infections each year. We do not know what infections will clear and which infections will not. We do know that the HPV vaccine includes strains that cause over 90% of HPV cancers, mitigating patient risk. Approximately 92 people each day are diagnosed with an HPV-attributable cancer. These patients and their families face the emotional impact of a cancer diagnosis, the challenges of cancer treatment, and the possibility of death. Health systems with missions to improve health, provide high-quality care, and serve their communities have been caring for these patients, as well as managing the high financial costs that accompany cancer care. Health systems are well positioned to expedite HPV vaccine uptake and help eliminate HPV cancers.
We have convened an advisory committee of industry and clinical experts that will provide guidance to the Collaborative on the development of objectives and educational content. The committee includes:
Tammy Beckham, DVM, Ph.D.
Associate Director, Resilient Supply Chain and Shortages Prevention Program
Food & Drug Administration
Ilka Chavez, M.P.A.
Chief of Operations and Management, National Vaccine Program Office (NVPO)
U.S. Department of Health and Human Services
Kara Elam, Ph.D., M.P.H., M.S.
Research and Policy Strategist
Office on Women's Health
Melissa Gilkey, Ph.D.
Assistant Professor, Department of Health Behavior
University of North Carolina’s Gillings School of Global Health
- Jonathan Hill, M.P.H.
Public Health Analyst
Centers for Disease Control and Prevention
Sarah Kobrin, Ph.D., M.P.H.
Chief of Health Systems and Research Branch
National Cancer Institute
Jason Maxwell, M.D.
Department Chair of Pediatrics and Practices
HealthPartners, Como Clinic
Kristin Oliver, M.D., M.H.S.
Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine and Public Health, Department of Pediatrics
Andrea Polkinghorn, B.S.N., RN-BC
Immunization Strategy Leader
Melinda Wharton, M.D., M.P.H.
Associate Director for Vaccine Policy
NCIRD at Centers for Disease Control and Prevention
If you have questions or need further information, contact Erin Leaver-Schmidt at email@example.com or by phone at 703.838.0033 ext. 390.>